TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antifungals
Research on antifungals detailed by V. Nagappan and co-authors
April 15th, 2008
"Posaconazole is a triazole antifungal agent with a spectrum of activity that includes Candida and Cryptococcus species, many molds, and some endemic fungi. Posaconazole has received US Food and Drug Administration approval for the treatment of oropharyngeal candidiasis, including infections refractory to itraconazole and/or fluconazole," researchers in the United States report. "It is also approved as prophylaxis for invasive Aspergillus and Candida infections in patients aged >= 13 years who are at high risk of developing these infections, in adult and adolescent hematopoietic stem cell transplant recipients with graft-versus-host disease, and in persons with...
Source: TB & Outbreaks Week (2008-04-15)
|
